Beruflich Dokumente
Kultur Dokumente
by
Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland
July 2012
AUTHOR'S
BIOGRAPHY
ABOUT
THIS
REPORT
Prof. Jain wrote the first report on Personalized Medicine in 1998, which was published
by Decision Resources Inc, USA. The second edition was published in 2001 by Informa
Publications, London. Since 2003, the report is published and continuously updated and
rewritten at Jain PharmaBiotech.
+4161-6924461
info@pharmabiotech.ch
http://pharmabiotech.ch/
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted
in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written
permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the
consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information
presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.
-2-
TABLE
OF
CONTENTS
-3-
-4-
-5-
-6-
-7-
-8-
-9-
- 10 -
- 11 -
10.
Introduction..................................................................................................................... 357
Non-genomic factors in the development of personalized medicine ................................. 357
Personalized medicine based on circadian rhythms ............................................................. 357
Cytomics as a basis for personalized medicine ................................................................... 358
Intestinal microflora ....................................................................................................... 358
Gut microbiome compared to human genome ............................................................... 358
Metabolic interactions of the host and the intestinal microflora ....................................... 359
Role of drug delivery in personalized medicine ................................................................... 359
Personalized approach to clinical trials .............................................................................. 360
Use of Bayesian approach in clinical trials..................................................................... 360
Individualzing risks and benefits in clinical trials............................................................ 360
Clinical trials of therapeutics and companion diagnostics ................................................ 361
Players in the development of personalized medicine ...................................................... 361
Personalized Medicine Coalition ........................................................................................ 362
European Personalized Medicine Diagnostics Association ................................................ 363
Role of pharmaceutical industry ....................................................................................... 363
Production and distribution of personalized medicines .................................................... 363
Role of biotechnology companies ..................................................................................... 364
- 12 -
- 13 -
11.
12.
Introduction..................................................................................................................... 433
Perceived financial concerns ............................................................................................ 433
Personalized medicine and orphan drug syndrome ............................................................. 433
Commercial aspects of pharmacogenomics ...................................................................... 433
Cost of DNA testing ........................................................................................................ 433
Cost of sequencing the human genome............................................................................. 434
Cost of genotyping ......................................................................................................... 436
Cost of pharmacogenomics-based clinical trials .................................................................. 436
Business development of pharmacogenomic companies ...................................................... 437
Cost of personalized healthcare ....................................................................................... 437
The rising healthcare costs in the US ................................................................................ 437
Reducing healthcare costs by combining diagnostics with therapeutics.................................. 438
Cost-effectiveness of pharmacogenetic testing .............................................................. 438
Cost-effectiveness of CYP genotyping-based pharmacotherapy ....................................... 439
Cost effectiveness of HIV genotyping in treatment of AIDS ............................................. 439
Cost-effectiveness of warfarin pharmacogenomics ......................................................... 440
Lowering the high costs of cancer chemotherapy .......................................................... 440
- 14 -
13.
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
- 15 -
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
9-5: Selected companies involved in developing personalized cancer therapies ....................... 353
10-1: Players in the development of personalized medicine .................................................. 361
10-2: Members of the Personalized Medicine Coalition ......................................................... 362
10-3: Biobanks relevant to personalized medicine ............................................................... 391
10-4: Role of bioinformatics in the development of personalized medicine .............................. 393
10-5: Advantages of personalized medicine for the biopharmaceutical industry ....................... 402
10-6: Advantages of personalized medicine for the patients ................................................. 402
10-7: Advantage of personalized medicine for the physicians ................................................ 403
10-8: Advantage of personalized medicine for the healthcare providers ................................. 403
10-9: Limitations of personalized medicine ......................................................................... 403
10-10: Methods of translational science that are relvant to personalized medicine ................... 407
10-11: Companies involved in predictive healthcare ............................................................ 409
11-1: Drugs with genetic information in their labels ............................................................. 427
12-1: Drivers for the development of personalized medicine ................................................. 441
12-2: Growth of markets relevant to personalized medicine 2011-2021 ................................. 444
12-3: Markets for personalized medicine according to therapeutic area 2011-2021 .................. 446
12-4: Markets for personalized medicine in major regions 2011-2021 .................................... 446
12-5: Lack of efficacy in current therapy ............................................................................ 447
12-6: Impact of personalized medicine on other industries ................................................... 447
12-7: Strategies to develop personalized medicine .............................................................. 448
12-8: Role of the Internet in development of personalized medicine ...................................... 449
Figures
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
- 16 -